Antagonistas de receptores opioides

Un compuesto seleccionado entre el grupo que consiste en: 6-{4-[2-(tetrahidro-piran-4-il)-etilamino]-ciclohexiloxi}-nicotinamida,**Fórmula** 5 6-[4-(3-metil-butilamino)-ciclohexiloxi]-nicotinamida,,**Fórmula** 6-[4-(2-tiofen-2-il-etilamino)-ciclohexiloxi]-nicotinamida,,**Fórmula** 4-[4-(3-fenil-propilamino)-ciclohexiloxi]-benzamida,,**Fórmula** Trans-6-(4-bencilamino)-ciclohexiloxi)-nicotinamida,,**Fórmula** 6-(1-piridin-2-ilmetil-piperidin-4-iloxi)-nicotinamida,**Fórmula** A compound of the formula (I) wherein the variables X1 to X5, R1 to R7 including R3', E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.